The PE Ratio as of November 2024 (TTM) for Cellectis S.A. (CLLS) is -1.61

According to Cellectis S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -1.61. This represents a change of -333.44% compared to the average of 0.69 of the last 4 quarters.

Cellectis S.A. (CLLS) Historical PE Ratio (quarterly & annually)

How has CLLS PE Ratio performed in the past?

The mean historical PE Ratio of Cellectis S.A. over the last ten years is 4.44K. The current -1.61 PE Ratio has changed -103.63% with respect to the historical average. Over the past ten years (40 quarters), CLLS's PE Ratio was at its highest in in the December 2014 quarter at 67.66. The PE Ratio was at its lowest in in the June 2018 quarter at -41.15.

Cellectis S.A. (CLLS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cellectis S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cellectis S.A. (CLLS) Average PE Ratio

How has CLLS PE Ratio performed in the past?

The current PE Ratio of Cellectis S.A. (CLLS) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Cellectis S.A. (CLLS) PE Ratio vs. Peers

How is CLLS’s PE Ratio compared to its peers?

Cellectis S.A.’s PE Ratio is greater than Sigilon Therapeutics, Inc. (-16.76), greater than DiaMedica Therapeutics Inc. (-9.26), less than NeuBase Therapeutics, Inc. (-0.20), greater than Soleno Therapeutics, Inc. (-18.45), less than Genfit S.A. (141.32), greater than Cyteir Therapeutics, Inc. (-9.12), greater than ERYTECH Pharma S.A. (-101.81), greater than Eliem Therapeutics, Inc. (-2.42), less than HCW Biologics Inc. (-0.78), greater than Innate Pharma S.A. (-3.71), less than Inhibrx Biosciences, Inc. (0.13), greater than Anebulo Pharmaceuticals, Inc. (-4.78), greater than Crinetics Pharmaceuticals, Inc. (-16.16), less than Passage Bio, Inc. (-0.45), greater than REGENXBIO Inc. (-2.04), less than LianBio (-0.75), greater than Kezar Life Sciences, Inc. (-5.71), greater than Foghorn Therapeutics Inc. (-5.38), less than Shattuck Labs, Inc. (-0.69), greater than Monte Rosa Therapeutics, Inc. (-5.83), greater than Kymera Therapeutics, Inc. (-20.45), greater than Nurix Therapeutics, Inc. (-9.07),

Build a custom stock screener for Cellectis S.A. (CLLS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cellectis S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cellectis S.A. (CLLS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cellectis S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.